CompletedPhase 4

Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery

United States248 participantsStarted 2022-03-01

Plain-language summary

Liposomal Bupivacaine (Exparel) has been recently studied as the active agent utilized in various nerve block. Due to its liposomal form allowing for extended delivery, Exparel has been used in various peri-operative nerve blocks among multiple orthopaedic specialties in hopes of achieving improved pain control and decreased opioid use. This study compares the efficacy and effect on opioid use of peripheral nerve blocks and local infiltration with and without Exparel in patients undergoing foot and ankle surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients undergoing elective orthopaedic foot and ankle surgery at a single institution * English speaking * Able to provide consent to surgery and study participation Exclusion Criteria: * Non-elective or emergent foot and ankle surgery * Non-english speaking * Does not possess medical decision making capacity

What they're measuring

Duration of block

Timeframe: 1 year

Trial details

NCT IDNCT05494645

SponsorSt. Luke's Hospital, Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-31

View on ClinicalTrials.gov More Pain, Postoperative trials